Literature DB >> 21264543

Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma.

Asli Nar1, Ozlem Ozen, Neslihan Bascil Tutuncu, Beyhan Demirhan.   

Abstract

Approximately 30% of patients with thyroid nodules have indeterminate or suspicious fine-needle aspiration (FNA) biopsy results. These patients usually undergo thyroidectomy because of cancer risk. Our aim was to determine diagnostic value of cyclin A and cyclin B1 immunohistochemistry added to routine cytology and their expression on histological sections. We studied the expression of cyclin A and cyclin B1 in FNA biopsies and resection specimens of 168 indeterminate or suspicious FNA biopsy results retrospectively at an academic hospital using immunohistochemistry. Malignant histopathology consisted 64 of resection specimens (58 papillary, 4 follicular, 1 medullary, and 1 Hürthle cell carcinoma). Cyclin A was overexpressed in 51.5% of malignant cases in contrast to 31.7% of 104 benign pathology specimens (P = 0.025). Cyclin B1 was positive in 39.1% of malignant specimens in contrast to 15.4% of benign cases (P = 0.001). Cyclin A overexpression was not linked to cyclin B1 overexpression. No association was found between overexpression of cyclin A, cyclin B1 and age, thyroiditis, multifocality, tumor size, extra-thyroidal extension, capsule infiltration, lymph node and distant organ metastases and TNM stage in malignant cases. Female patients with thyroid carcinoma overexpressed significantly more cyclin B1 than male patients (P = 0.015). Retrospective analysis of cyclin A and cyclin B1 in FNA biopsies yielded negative results for both benign and malignant cases. In conclusion, cyclin A and cyclin B1 are useful markers in the distinction of benign and malignant thyroid tumors and can increase diagnostic accuracy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21264543     DOI: 10.1007/s12032-010-9800-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  38 in total

Review 1.  Cost-effective management of thyroid nodules and nodular thyroid goiters.

Authors:  Edwin Supit; Alan N Peiris
Journal:  South Med J       Date:  2002-05       Impact factor: 0.954

2.  Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment.

Authors:  L E Sanders; B Cady
Journal:  Arch Surg       Date:  1998-04

3.  Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.

Authors:  P S de Matos; A P Ferreira; F de Oliveira Facuri; L V M Assumpção; K Metze; L S Ward
Journal:  Histopathology       Date:  2005-10       Impact factor: 5.087

4.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions.

Authors:  A Bartolazzi; A Gasbarri; M Papotti; G Bussolati; T Lucante; A Khan; H Inohara; F Marandino; F Orlandi; F Nardi; A Vecchione; R Tecce; O Larsson
Journal:  Lancet       Date:  2001-05-26       Impact factor: 79.321

5.  Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.

Authors:  E Saggiorato; R De Pompa; M Volante; S Cappia; F Arecco; A P Dei Tos; F Orlandi; M Papotti
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

6.  Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival.

Authors:  S Aaltomaa; M Eskelinen; P Lipponen
Journal:  Prostate       Date:  1999-02-15       Impact factor: 4.104

7.  Expression of G2-M modulators in thyroid neoplasms: correlation of cyclin A, B1 and cdc2 with differentiation.

Authors:  Yasuhiro Ito; Hiroshi Yoshida; Keiichi Nakano; Yuuki Takamura; Kaoru Kobayashi; Tamotsu Yokozawa; Fumio Matsuzuka; Nariaki Matsuura; Kanji Kuma; Akira Miyauchi
Journal:  Pathol Res Pract       Date:  2002       Impact factor: 3.250

8.  Expression of the G2-M modulators in pancreatic adenocarcinoma.

Authors:  Yasuhiro Ito; Tsutomu Takeda; Ken-ichi Wakasa; Masahiko Tsujimoto; Masanao Okada; Nariaki Matsuura
Journal:  Pancreatology       Date:  2002       Impact factor: 3.996

9.  Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration.

Authors:  R M Tuttle; H Lemar; H B Burch
Journal:  Thyroid       Date:  1998-05       Impact factor: 6.568

Review 10.  Management of thyroid incidentalomas.

Authors:  Robert J Silver; Sareh Parangi
Journal:  Surg Clin North Am       Date:  2004-06       Impact factor: 2.741

View more
  7 in total

1.  Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.

Authors:  Shweta Kotian; Lisa Zhang; Myriem Boufraqech; Kelli Gaskins; Sudheer Kumar Gara; Martha Quezado; Naris Nilubol; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2017-06-09       Impact factor: 12.531

Review 2.  Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.

Authors:  Mitra Zabihi; Ramin Lotfi; Amir-Mohammad Yousefi; Davood Bashash
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-04       Impact factor: 4.553

3.  Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.

Authors:  Andrii Dinets; Mykola Hulchiy; Anastasios Sofiadis; Mehran Ghaderi; Anders Höög; Catharina Larsson; Jan Zedenius
Journal:  Eur J Endocrinol       Date:  2012-03-28       Impact factor: 6.664

Review 4.  Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Authors:  Marion Peyressatre; Camille Prével; Morgan Pellerano; May C Morris
Journal:  Cancers (Basel)       Date:  2015-01-23       Impact factor: 6.639

5.  Inhibition of cyclinB1 Suppressed the Proliferation, Invasion, and Epithelial Mesenchymal Transition of Hepatocellular Carcinoma Cells and Enhanced the Sensitivity to TRAIL-Induced Apoptosis.

Authors:  Shuai Lv; Hanbing Ning; Yingxia Li; Jingyun Wang; Qiaoyu Jia; Hongtao Wen
Journal:  Onco Targets Ther       Date:  2020-02-05       Impact factor: 4.147

6.  The intercorrelation among CCT6A, CDC20, CCNB1, and PLK1 expressions and their clinical value in papillary thyroid carcinoma prognostication.

Authors:  Wei Peng; Wenqiang Li; Xiaoyong Zhang; Weili Cen; Yanan Liu
Journal:  J Clin Lab Anal       Date:  2022-07-15       Impact factor: 3.124

7.  Cell cycle regulation and anticancer drug discovery.

Authors:  Jingwen Bai; Yaochen Li; Guojun Zhang
Journal:  Cancer Biol Med       Date:  2017-11       Impact factor: 4.248

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.